Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-21-000027
Filing Date
2021-04-29
Accepted
2021-04-29 16:52:25
Documents
46
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20210331x10q.htm 10-Q 798697
2 EX-31.1 sava-20210331xex31_1.htm EX-31.1 25409
3 EX-31.2 sava-20210331xex31_2.htm EX-31.2 25108
4 EX-32.1 sava-20210331xex32_1.htm EX-32.1 20291
5 GRAPHIC sava-20210331x10qg001.jpg GRAPHIC 21931
6 GRAPHIC sava-20210331x10qg002.jpg GRAPHIC 604306
  Complete submission text file 0001069530-21-000027.txt   3895190

Data Files

Seq Description Document Type Size
7 EX-101.INS sava-20210331.xml EX-101.INS 509658
8 EX-101.SCH sava-20210331.xsd EX-101.SCH 25984
9 EX-101.CAL sava-20210331_cal.xml EX-101.CAL 27417
10 EX-101.DEF sava-20210331_def.xml EX-101.DEF 71219
11 EX-101.LAB sava-20210331_lab.xml EX-101.LAB 204114
12 EX-101.PRE sava-20210331_pre.xml EX-101.PRE 170220
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 21871606
SIC: 2834 Pharmaceutical Preparations